Citation
Uzu, Takashi, et al. "Target for Glycemic Control in Type 2 Diabetic Patients On Hemodialysis: Effects of Anemia and Erythropoietin Injection On Hemoglobin A(1c)." Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, vol. 13, no. 2, 2009, pp. 89-94.
Uzu T, Hatta T, Deji N, et al. Target for glycemic control in type 2 diabetic patients on hemodialysis: effects of anemia and erythropoietin injection on hemoglobin A(1c). Ther Apher Dial. 2009;13(2):89-94.
Uzu, T., Hatta, T., Deji, N., Izumiya, T., Ueda, H., Miyazawa, I., Kanasaki, M., Isshiki, K., Nishio, T., & Arimura, T. (2009). Target for glycemic control in type 2 diabetic patients on hemodialysis: effects of anemia and erythropoietin injection on hemoglobin A(1c). Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 13(2), 89-94. https://doi.org/10.1111/j.1744-9987.2009.00661.x
Uzu T, et al. Target for Glycemic Control in Type 2 Diabetic Patients On Hemodialysis: Effects of Anemia and Erythropoietin Injection On Hemoglobin A(1c). Ther Apher Dial. 2009;13(2):89-94. PubMed PMID: 19379146.
TY - JOUR
T1 - Target for glycemic control in type 2 diabetic patients on hemodialysis: effects of anemia and erythropoietin injection on hemoglobin A(1c).
AU - Uzu,Takashi,
AU - Hatta,Tsuguru,
AU - Deji,Naoko,
AU - Izumiya,Tamani,
AU - Ueda,Hisami,
AU - Miyazawa,Itsuko,
AU - Kanasaki,Masami,
AU - Isshiki,Keiji,
AU - Nishio,Toshiji,
AU - Arimura,Tetsuro,
PY - 2009/4/22/entrez
PY - 2009/4/22/pubmed
PY - 2009/7/17/medline
SP - 89
EP - 94
JF - Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
JO - Ther Apher Dial
VL - 13
IS - 2
N2 - In hemodialysis (HD) patients the glycated hemoglobin (Hb(A1c)) level may underestimate glycemic control. The aim of this study is to estimate accurate glycemic control in type 2 diabetic patients on HD. Type 2 diabetes patients (N = 87) who had been receiving maintenance HD for at least one year were enrolled. Hb(A1c) and the percentage of glycated albumin relative to total the serum albumin (%GA) were measured in blood samples and the factors that affected the %GA/Hb(A1c) ratio were examined. There were significant and positive correlations between the plasma glucose and either the Hb(A1c) levels (r = 0.539, P < 0.01) or the %GA level (r = 0.520, P < 0.01). No relationship between the serum albumin levels and %GA levels was observed. A weekly dose of erythropoietin (EPO) was positively correlated with the ratio of %GA/Hb(A1c) and hematocrit (Ht) correlated negatively. There was no significant correlation between the %GA/Hb(A1c) level and the EPO dose in patients with Ht > or = 30%, although a significant correlation was found between those parameters in the Ht < 30% group. The mean of the %GA/Hb(A1c) ratios in patients with Ht > or = 30%, with Ht < 30% and treated with EPO < 100 IU/kg/week, and with Ht < 30% and treated with EPO > or = 100 IU/kg/week were 3.41, 3.56 and 4.13, respectively. In HD patients, accurate glycemic control may be estimated as: Hb(A1c) x 1.14 if Ht > or = 30%; Hb(A1c) x 1.19 if Ht < 30% and treated with low dosages of EPO; and Hb(A1c) x 1.38 if Ht < 30% and treated with high dosages of EPO.
SN - 1744-9987
UR - https://www.unboundmedicine.com/medline/citation/19379146/Target_for_glycemic_control_in_type_2_diabetic_patients_on_hemodialysis:_effects_of_anemia_and_erythropoietin_injection_on_hemoglobin_A_1c__
L2 - https://doi.org/10.1111/j.1744-9987.2009.00661.x
DB - PRIME
DP - Unbound Medicine
ER -